William Blair analyst Myles Minter has reiterated their bullish stance on IONS stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors that highlight Ionis Pharmaceuticals’ strong performance and promising future prospects. The company reported a robust quarter, surpassing both internal and consensus estimates, driven by the rapid commercial uptake of Tryngolza in the familial chylomicronemia syndrome (FCS) market. This success underscores Ionis’ potential to expand its market presence and revenue streams.
Minter also points to the upcoming CORE trial data presentations at the American Heart Association, which are expected to support broader prescribing and payer coverage for olezarsen in severe hypertriglyceridemia (sHTG). The company’s strategic positioning with multiple clinical catalysts, including five Phase III readouts anticipated in 2026, further strengthens its growth trajectory. With Ionis evolving into a diversified commercial franchise, Minter believes it presents a compelling investment opportunity.
According to TipRanks, Minter is a 5-star analyst with an average return of 30.1% and a 61.69% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Biogen, and Arcturus Therapeutics.
In another report released today, Needham also maintained a Buy rating on the stock with a $90.00 price target.